PRIME MEDICINE INC

PRMENASDAQ

🏆 #2279 by market capEarnings Nov 6US Equity

$3.26▲ $0.11 (+3.49%)

🌙 After hours$3.26▲ 0.00%Regular close · extended-hours price shown

1h—

24h▲ 3.5%

7d▲ 5.8%

14d▲ 6.9%

30d▼ 7.1%

1y▼ 5.5%

🏦Market Cap

$589M

Small Cap

📈Revenue Growth (YoY)

-17.9%

Declining

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

140.3x

Expensive

Otter Score

Fair

Trading Snapshot

Day Range: $3.21 – $3.28
52-Week Range: $2.67 – $6.94
Volume: $4.00B
Avg Volume: $5.24B
Shares Outstanding: 180.6M
Next Earnings: Sep 4, 2026

Fundamentals Snapshot

Annual Revenue: $5M
Last Q Revenue: $1M
P/E Ratio: —
P/S Ratio: 140.3x
EPS (TTM): $-1.09
Dividend Yield: —

Why Investors Own PRME

✓High-growth profile — revenue up -3.0% YoY with expanding US Equity exposure.
✓Healthy economics — 44% gross margin and 18% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$5M▼ −3.2% YoY

Gross Margin (TTM)

43.9%▲ +3.9% YoY

Operating Income (TTM)

$458,568▼ −3.2% YoY

Free Cash Flow (TTM)

$838,392▼ −3.2% YoY

About PRIME MEDICINE INC

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.

🦦